These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34337490)

  • 1. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
    Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
    Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.
    Waldén M; Aldrimer M; Lagerlöf JH; Eklund M; Grönberg H; Nordström T; Palsdottir T
    Eur Urol Open Sci; 2022 Apr; 38():32-39. PubMed ID: 35495282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
    Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
    Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
    [No Abstract]   [Full Text] [Related]  

  • 5. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
    Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
    Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
    Andersson J; Palsdottir T; Lantz A; Aly M; Grönberg H; Egevad L; Eklund M; Nordström T
    Eur Urol Open Sci; 2022 Oct; 44():69-75. PubMed ID: 36185581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
    Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External Validation of Stockholm3 in a Retrospective German Clinical Cohort.
    Tilki D; Rejek N; Nohe F; Haese A; Graefen M; Thederan I
    Eur Urol Focus; 2024 Aug; ():. PubMed ID: 39112137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
    Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging.
    Palsdottir T; Nordström T; Aly M; Jäderling F; Clements M; Grönberg H; Eklund M
    Eur Urol Oncol; 2019 Sep; 2(5):490-496. PubMed ID: 31412016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.
    Vigneswaran HT; Palsdottir T; Olsson H; Haug ES; Picker W; Löffeler S; Grönberg H; Eklund M; Nordström T
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):457-464. PubMed ID: 33168965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
    Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.
    Palsdottir T; Söderbäck H; Jäderling F; Bergman M; Vigneswaran H; Grönberg H
    Eur Urol Open Sci; 2024 Mar; 61():29-36. PubMed ID: 38384438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort.
    Elyan A; Saba K; Sigle A; Wetterauer C; Engesser C; Püschel H; Attianese S; Maurer P; Deckart A; Cathomas R; Strebel RT; Gratzke C; Seifert HH; Rentsch CA; Mortezavi A
    Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37813730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
    Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
    Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience.
    Viste E; Vinje CA; Lid TG; Skeie S; Evjen-Olsen Ø; Nordström T; Thorsen O; Gilje B; Janssen EAM; Kjosavik SR
    Scand J Prim Health Care; 2020 Sep; 38(3):315-322. PubMed ID: 32772613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
    Vigneswaran HT; Eklund M; Discacciati A; Nordström T; Hubbard RA; Perlis N; Abern MR; Moreira DM; Eggener S; Yonover P; Chow AK; Watts K; Liss MA; Thoreson GR; Abreu AL; Sonn GA; Palsdottir T; Plym A; Wiklund F; Grönberg H; Murphy AB;
    J Clin Oncol; 2024 Jul; ():JCO2400152. PubMed ID: 39038251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
    Nordström T; Adolfsson J; Grönberg H; Eklund M
    BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.